A LL comorbidity measures segregate study participants into those who are healthier and those who are less healthy. The objective of this review is to examine how well researchers can expect to have achieved this goal, given the variable axis for which they are measuring comorbidity, the comorbidity measure they select, and the analytic method they choose.
ANALYTIC STRATEGIES FOR MEASURING COMORBIDITY
We first describe strategies for constructing indices of comorbidity or multiple morbidities, focusing on their advantages and disadvantages (Table 1) . A sum of the number of diagnoses from among a list of candidate diagnoses provides an ordinal score. This method has the advantage of conceptual simplicity and ease of data ascertainment, but there are disadvantages. First, all diagnoses are scored equivalently. For many analytic relations, different diseases as well as their severity will affect outcomes differently. This disadvantage can be addressed by weighting the contributions of different diseases, depending on their role in the analytic relationship. Weighting schemes can also take into account treatment. If, however, weightings are overly customized to specific diseases, the index will be less useful when applied in other settings. Second, analytic strategies often force a linear relationship with the ordinal scale across its entire range. A participant moving from the zero score to one comorbid disease could realize the majority of the comorbidity effect, with additional unit increases having a diminishing impact. Categorizing summed scores, rather than treating the index as an ordinal variable, addresses this disadvantage. The third disadvantage of a summed measure is that it ignores potentially important relationships between diseases that might differ from their simple sum. The interaction between chronic obstructive pulmonary disease and congestive heart failure might exceed the simple sum, whereas cardiovascular disease related to diabetes might be overweighted in an index that counts both independently. These problems may be reduced if a condition must reach a clinical threshold before being counted. In addition, individual diseases counted separately in an index might arise from a common cause, whether that cause is exogenous (e.g., tobacco smoke) or endogenous (e.g., inflammatory response). The impact of the clustering of individual diseases with a common pathologic mechanism may be lesser or greater than the simple sum. Furthermore, all of the extant measures-regardless of whether they are based on simple counts or a sum of individually weighted conditionsassume an additive relationship for the included diseases.
DATA SOURCES AVAILABLE TO MEASURE COMORBIDITY
All comorbidity indices rely on medical record information, patient self-report, clinical judgment, or large administrative databases. Regardless of the data source, errors can be introduced into the construction of the index during data collection. In addition, patients with cognitive impairment may underreport symptoms of other conditions (1) and may be seen less frequently by their physicians, resulting in an underrecognition or undertreatment of other conditions (2) . Both of these biases will affect the accuracy of measurement of comorbidity, particularly in older populations, regardless of the data source.
Medical Records
Many comorbidity indices rely on medical records [e.g., Charlson Index (3), Cumulative Illness Rating Scale (4), Index of Coexistent Diseases (5), and Kaplan-Feinstein Index (6) ]. An important advantage of medical records is the good correspondence between diagnosed conditions and the disease entities ordinarily included in comorbidity indices. Another important advantage is that medical records reflect the information available to clinicians treating the patient/study participant. As comorbidity indices are often meant to reflect the impact of coexistent diseases on medical decision making, this close correspondence assures that the index reflects the target concept.
Using medical records as a data source also has important disadvantages. First, review of records is a resourceintensive method of data collection. Second, medical record review requires patient consent and consent of the health care provider and/or the health care organization. Third, it usually requires validation substudies to assure sufficient intra-rater and inter-rater reliability. Fourth, medical records must be available over a sufficient period of time to assure that the comorbidity index can be accurately constructed. Fifth, the quality of the medical record data may be different for inpatient than for outpatient care.
Patient Self-Report
Some comorbidity indices have been developed to collect information directly from patients [e.g., the Comorbidity Symptom Scale (7), Geriatric Index of Comorbidity (8), or Total Illness Burden Index (9)]. Other comorbidity indices originally intended to use medical records as the data source have been adapted for patient self-report [e.g., the Katz adaptation of the Charlson Index to patient interview (10)]. Self-report of comorbidity correlates well with data collected by medical record review (11) . Two advantages of self-report compared with medical record review are its more limited resource requirements and its potential for being more complete. Patients can be asked to recall their entire medical history, whereas medical records may be limited to a time period that does not include all relevant history. In contrast, in studies of large populations, or when patients are in hospitals or nursing homes, the cost of interviewing may be prohibitive. Furthermore, cognitive impairment can adversely affect recall accuracy. The availability of electronic medical records is increasingly affecting the balance of resource requirements between medical record review and patient recruitment and interview.
Despite the adequate correlation between comorbidity scores obtained from patient interview and from medical record review, the most important disadvantage of patient recall is its potential for measurement error. The greatest concern is that errors in recalling or reporting comorbidity data will correlate with errors in recall or reporting of other study variables. These dependent errors can substantially bias estimates of effect.
Clinical Judgment
A simple and efficient method of collecting comorbidity information is to collect an overall rating of patients' health status from their physicians, such as the American Society of Anesthesiologists Index. The advantages of these ratings are: (a) simplicity, which translates to low resource requirements, (b) independence, which precludes dependent errors associated with errors in interview data, and (c) good correspondence with physician impressions that affect medical decision making.
The major disadvantage of these ratings is also their simplicity, because the simplicity masks the true complexity of comorbidity. A second disadvantage is that patient consent will be required to obtain the rating from the physician or to review medical records. If the rating is the only information obtained from physicians directly or from medical record review, then the efficiency of data collection will be poor.
Administrative Databases
Administrative databases, such as claims databases [e.g., the Diagnostic Cost Group/Hierarchical Condition Categories (11) and pharmacy databases (see the Chronic Disease Score; 12)] have been used to construct comorbidity indices. These indices translate information gathered for an unrelated primary purpose to a secondary purpose of scaling comorbidity. The translation will be inevitably imperfect. For example, claims databases contain information intended to maximize reimbursement, so this information may inflate the burden of comorbid diseases. The quality of the claims data may also be better for inpatient services than for outpatient services. Use of pharmacy databases requires that all participants had uniform access to reimbursement for relevant pharmaceuticals and that all participants used only the pharmacy housing the database to obtain prescriptions. The advantages of using administrative data are: (a) fewer resources required to collect comorbidity data than medical record review and patient interview, particularly given very large study populations, and (b) independence of errors in measurement of comorbidity from errors in measurement of other study variables collected by other methods. An important disadvantage of administrative databases is that specialized expertise is required to obtain administrative data and to manipulate them. Certain scales derived from one data source can be adapted to administrative databases [the Deyo adaptation of the Charlson index (13)].
The Minimum Data Set has been used to assess comorbidity in nursing home residents (14) . This work combines the medical record, clinical rating, and administrative data perspectives. These data are used to assess comorbidity in the population of postacute patients leaving the hospital and returning home via a nursing home.
VARIABLE AXES
There are four variable axes for which measurement of comorbidity might be required: confounder, modifier, exposure, and outcome. All measures of comorbidity are imperfect surrogates because of: (a) poor correspondence between the measure and the target conceptual entity, (b) the difficulty in determining whether comorbid conditions precede, are concurrent with, or postdate outcomes, (c) and data limitations. As a result, study participants can be misclassified. Below we review the expected effect of misclassification of comorbidity when it is used in each variable axis (see also Table 2 ).
Comorbidity as Confounder
When comorbidity is a confounder, and because there is no perfect measure, there will be imperfect control for confounding. The relative risk due to confounding measures the direction and magnitude of confounding:
When misclassification of comorbidity is nondifferential (i.e., rates of misclassification of comorbidity are expected to be homogeneous across strata of the dependent and independent variables) and nondependent (i.e., errors in misclassification of comorbidity are not expected to correlate with errors in classification of the dependent or independent variables), the relative risk due to confounding (RR confounding ) is expected to be biased toward the null. The result is that the adjusted estimate of effect (e.g., RR adjusted ) is biased toward the crude estimate of effect (e.g., RR crude ). Under these circumstances, estimates of effect adjusted for the imperfect measure of comorbidity by modeling, pooling, or standardization will lie between the true adjusted effect and the unadjusted estimate of effect. Were comorbidity misclassified differentially or dependently, the direction of the error in the relative risk due to confounding would still be correctable, but the bias before correction would not be predictable.
In general, when comorbidity is prevalent, its relative risk due to confounding is non-negligible (15) . There is opportunity for substantial bias even with nondifferential and nondependent misclassification because the relative risk due to confounding may be far from the null. When comorbidity is uncommon, however, its relative risk due to confounding will be negligible. The contrasting impact of comorbidity and its misclassification when comorbidity is prevalent, versus when it is rare, illustrates the importance of accurate measurement of comorbidity in older populations in whom comorbid disease is prevalent.
Comorbidity as Modifier
Researchers may wish to investigate whether the relationship between an independent and dependent variable is different depending on the level of comorbidity. For example, one might investigate the relationship between therapy and survival. One might then stratify the analysis by levels of comorbidity to examine whether the effect is similar across levels. These analyses examine effect measure modification, interdependence, or interaction. Although these have subtle differences, they share in common the potential for misleading results when either the exposure variable or modifying variable is misclassified. When comorbidity is the modifying variable and is subject to misclassification, effect measure modification (or interdependence or interaction) may appear, when in truth there is none (16) . Conversely, when comorbidity is the main effect Estimates of effect at the extremes of a comorbidity scale will be biased towards the null; Estimates of effect at intermediate values will be biased towards or away from the null Outcome
Estimates of effect will be biased toward the null; Dichotomization of comorbidity with near perfect specificity yields an unbiased estimate variable, true effect measure modification may be masked by the misclassification of the modifying variable.
Comorbidity as Exposure
Nondifferential, nondependent misclassification of a dichotomized measure of comorbidity as the exposure variable usually biases the estimate of effect toward the null. When comorbidity is analyzed as a continuous or ordinal variable, however, its mismeasurement or misclassification can have unpredictable consequences on the estimate of effect (17) (18) (19) . If errors in classification of the independent variable are correlated with errors in classification of the dependent variable, the estimate of effect can be substantially biased, even with only small error rates (20) , particularly if the exposure and outcome are rare. Dependent errors can be avoided by assuring that the exposure (comorbidity) and outcome are ascertained by different data collection methods. When both are ascertained by the same method, such as patient interview, dependent errors can easily account for all of an apparently important estimate of effect (21, 22) .
Comorbidity as Outcome
Nondifferential and nondependent misclassification of comorbid disease status, when it is dichotomized as the outcome variable, biases difference estimates of effect toward the null. Ratio measures of effect will be unbiased, however, when specificity is perfect (23) . Thus, investigators who wish to study comorbidity as a dependent variable ought to set a threshold for comorbid disease status and operationalize it as a dichotomous outcome. The threshold above which participants are classified as having comorbid disease ought to be high. A high threshold assures few false-positive cases, which is a requirement to achieve the advantage of the unbiased estimate of effect. In addition, the data collection methods selected should assure independence of comorbid disease scoring from other study variables.
NEW DIRECTIONS IN MEASUREMENT OF COMORBIDITY

Sensitivity Analysis
All comorbidity measures are surrogates for an unmeasurable gold standard. For example, all comorbidity measures rely on the quality of diagnostic testing, which may vary with patient age, sex, system of care, health insurance type, race/ ethnicity, or socioeconomic status. Differences in comorbidity related to these factors reflect the combination of real differences and differences attributable to variation in the quality of diagnostic testing. The deviation of the analysis from its ideal is a function of measurement error. Other sources of measurement error include errors in reporting, recording, or abstracting comorbid conditions. Quantitative sensitivity analysis is a solution to adjust estimates of effect for errors in classification (24) and to expand intervals so that they reflect total error, rather than only random error (25) (26) (27) (28) . Quantitative sensitivity analysis proves especially effective when errors in classification can be modeled as a function of well-measured variables, such as age or gender, in the analysis (29) .
Multiple Informants
A second approach to assessing comorbidity takes advantage of the circumstance in which several measures of comorbidity are available in the same data set. Comparisons have been made between information sources-examining medical record-based sources versus interview sources (30) (31) (32) or administrative claims-based sources (33, 34) -and between different measures of comorbidity (31, 34, 35) . Often all measures are marginally correlated with one another (30, 31, 33, 34) and add little control for confounding when a second index supplements the first (31, 33, 35) . Rather than searching for the best source of information or the best index, we have applied a multiple informants regression approach to measure the effect of comorbid disease on health outcomes and to control for its confounding impact (37) . The multiple informants approach merges parallel streams of information into the regression equations from all independent sources or indices to yield a single measure of the effect of comorbid disease, and simultaneously allows an examination of whether the individual indices have different effects. The multiple informants approach is ideally suited for this context, because all indices measure the same fundamental concept and because no index of comorbid diseases or method of data collection has consistently proved superior (37) .
Solutions From Other Fields
Research on comorbid disease has focused on developing measures appropriate for particular research questions, data collection methods, and patient populations. This focus has generated a proliferation of ever more specific measures. Two other observational sciences-health risk assessment and economics-have confronted similar problems and have responded by developing methods that quantify uncertainty. While this effort has not excluded research to improve methods and to improve measurement, the parallel development of methods to quantify uncertainty has yielded more defensible estimates of associations. Epidemiology has also recently re-emphasized uncertainty assessment, using techniques such as marginal structural models, multiple bias modeling, data augmentation, and multiple-imputation. As many of the challenges confronted by researchers who wish to improve assessment of comorbidity can be framed as measurement error problems or classification error problems, these techniques might be used to address uncertainty arising from the imperfect measurement of comorbid disease.
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